Physician profile
Yong Ji
NPI 1518963875
$6,590.42
in general payments reported to CMS, 2019-2025
24 companies · $2,338 in 2025
The $2,338 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.09 · 2020: $2,350 · 2021: $95.00 · 2022: $118 · 2023: $512 · 2024: $1,133 · 2025: $2,338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,534 · Consulting Fee: $1,050 · Education: $399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,533.96 |
| Consulting Fee | $1,050.00 |
| Education | $398.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,836.32 | 2019-2025 | Lynparza, Tagrisso, Imfinzi |
| Astellas Pharma US INC | $437.68 | 2023-2025 | Vyloy, Xtandi |
| Seagen INC. | $294.94 | 2021-2025 | |
| Janssen Biotech, INC. | $289.37 | 2024-2025 | Carvykti, Rybrevant, Darzalex |
| Incyte Corporation | $278.63 | 2025 | Jakafi, Jakafi, Monjuvi |
| Exelixis INC. | $209.46 | 2019-2025 | Cabometyx |
| Abbvie INC. | $143.31 | 2025 | |
| Servier Pharmaceuticals LLC | $140.00 | 2023 | |
| Beone Medicines USA, INC. | $133.50 | 2025 | Tevimbra |
| Stemline Therapeutics INC. | $131.44 | 2025 | Orserdu |
| Pharmacosmos Therapeutics INC. | $121.83 | 2025 | Cosela |
| E.R. Squibb & Sons, L.L.C. | $118.44 | 2022 | |
| Novartis Pharmaceuticals Corporation | $104.34 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $50.00 | 2024 | Onivyde |
| Eisai INC. | $50.00 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $46.32 | 2023 | Vonvendi |
| Pfizer INC. | $43.56 | 2025 | |
| Genentech USA, INC. | $36.30 | 2023 | Tecentriq |
| Genzyme Corporation | $32.46 | 2023 | |
| Daiichi Sankyo INC. | $26.39 | 2025 | Datroway |
| Jazz Pharmaceuticals INC. | $20.33 | 2025 | |
| Caris Mpi, INC. | $18.03 | 2025 | Mi Cancer Seek |
| Morphosys, US INC. | $13.96 | 2023 | Monjuvi |
| Bayer Healthcare Pharmaceuticals INC. | $13.81 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yong Ji listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.